Trial Profile
A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 23 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 23 Mar 2023 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2024.
- 02 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.